MX2024011665A - Induccion de tolerancia especifica de alfa-sinucleina mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson. - Google Patents

Induccion de tolerancia especifica de alfa-sinucleina mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson.

Info

Publication number
MX2024011665A
MX2024011665A MX2024011665A MX2024011665A MX2024011665A MX 2024011665 A MX2024011665 A MX 2024011665A MX 2024011665 A MX2024011665 A MX 2024011665A MX 2024011665 A MX2024011665 A MX 2024011665A MX 2024011665 A MX2024011665 A MX 2024011665A
Authority
MX
Mexico
Prior art keywords
disease
parkinson
mhc
synuclein
specific tolerance
Prior art date
Application number
MX2024011665A
Other languages
English (en)
Spanish (es)
Inventor
Valentin Bruttel
Jörg Wischhusen
Chi Wang Ip
Original Assignee
Univ Wuerzburg J Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wuerzburg J Maximilians filed Critical Univ Wuerzburg J Maximilians
Publication of MX2024011665A publication Critical patent/MX2024011665A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024011665A 2022-03-24 2023-03-24 Induccion de tolerancia especifica de alfa-sinucleina mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson. MX2024011665A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22164123.6A EP4249506A1 (en) 2022-03-24 2022-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease
PCT/EP2023/057682 WO2023180548A1 (en) 2022-03-24 2023-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Publications (1)

Publication Number Publication Date
MX2024011665A true MX2024011665A (es) 2024-09-27

Family

ID=81384775

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011665A MX2024011665A (es) 2022-03-24 2023-03-24 Induccion de tolerancia especifica de alfa-sinucleina mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson.

Country Status (12)

Country Link
US (1) US20250205321A1 (enExample)
EP (2) EP4249506A1 (enExample)
JP (1) JP2025514872A (enExample)
KR (1) KR20240162549A (enExample)
CN (1) CN119317639A (enExample)
AU (1) AU2023238805A1 (enExample)
CA (1) CA3250917A1 (enExample)
CL (1) CL2024002724A1 (enExample)
CO (1) CO2024012329A2 (enExample)
IL (1) IL314741A (enExample)
MX (1) MX2024011665A (enExample)
WO (1) WO2023180548A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025061918A1 (en) * 2023-09-22 2025-03-27 Julius-Maximilians-Universität Würzburg Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3063959A1 (en) 2017-05-23 2018-11-29 Julius-Maximilians-Universitat Wurzburg Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation

Also Published As

Publication number Publication date
EP4499682A1 (en) 2025-02-05
AU2023238805A1 (en) 2024-07-18
WO2023180548A1 (en) 2023-09-28
CL2024002724A1 (es) 2025-02-14
KR20240162549A (ko) 2024-11-15
JP2025514872A (ja) 2025-05-12
IL314741A (en) 2024-10-01
US20250205321A1 (en) 2025-06-26
CA3250917A1 (en) 2023-09-28
CN119317639A (zh) 2025-01-14
EP4249506A1 (en) 2023-09-27
CO2024012329A2 (es) 2024-09-30

Similar Documents

Publication Publication Date Title
ZA202104287B (en) Novel fusion proteins specific for cd137 and gpc3
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
ATE535252T1 (de) Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit
SA523442921B1 (ar) جزيئات ربط علاجية
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
RU2013114743A (ru) Композиции и способы для топического нанесения и трансдермальной доставки ботулинических токсинов
PH12021550001A1 (en) Novel fusion protein specific for cd137 and pd-l1
Xie et al. Therapeutic effects of human umbilical cord mesenchymal stem cells transplantation on hypoxic ischemic encephalopathy
BRPI0514199A (pt) método de efetuar profilaxia ou tratar uma doença, composição farmacêutica, anticorpo monoclonal, célula de hibridoma, e, método de triar um agente, de humanizar anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7 e de produzir uma forma quimérica de anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
GEP20257842B (en) High affinity antibodies targeting tau phosphorylated at serine 413
MX2012005864A (es) Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
WO2020132368A4 (en) T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
BR0314373A (pt) Produto imunogênico estável para a indução de anticorpos contra uma ou várias proteìnas antigênicas em um indivìduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
Lee et al. Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer
MX2024014979A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer
WO2023201234A3 (en) Anti-variable muc1* antibodies and uses thereof
MX2023010661A (es) Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas.
MX2023003890A (es) Molecula de interleucina-2 (il-2) modificada y uso de la misma.
MX2024011666A (es) Inmunosupresion especifica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo.
CO2024012329A2 (es) Inducción de tolerancia específica de alfa-sinucleína mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson
WO2023180546A8 (en) Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease
EE05293B1 (et) RG1 polpeptiidiga seonduv antikeha, seda h?lmav immunkonjugaat ja nende kasutamine
MX2024011668A (es) Inmunosupresion especifica del antigeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1.
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis